東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Artificial intelligence in drug design /

FindBook

Google Book

Amazon

博客來

Artificial intelligence in drug design /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Artificial intelligence in drug design // edited by Alexander Heifetz.
出版者:	New York, NY :Humana Press, : 2022.,
面頁冊數:	xi, 529 p. :ill. (some col.) ;27 cm.
內容註:	Applications of Artificial Intelligence in Drug Design: Opportunities and Challenges -- Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints -- Fighting COVID-19 with Artificial Intelligence -- Application of Artificial Intelligence and Machine Learning in Drug Discovery -- Deep Learning and Computational Chemistry -- Has Drug Design Augmented by Artificial Intelligence Become a Reality? -- Network Driven Drug Discovery -- Predicting Residence Time of GPCR Ligands with Machine Learning -- De Novo Molecular Design with Chemical Language Models -- Deep Neural Networks for QSAR -- Deep Learning in Structure-Based Drug Design -- Deep Learning Applied to Ligand-Based De Novo Drug Design -- Ultra-High Throughput Protein-Ligand Docking with Deep Learning -- Artificial Intelligence and Quantum Computing as the Next Pharma Disruptors -- Artificial Intelligence in Compound Design -- Artificial Intelligence, Machine Learning, and Deep Learning in Real Life Drug Design Cases -- Artificial Intelligence-Enabled De Novo Design of Novel Compounds that are Synthesizable -- Machine Learning from Omics Data -- Deep Learning in Therapeutic Antibody Development -- Machine Learning for In Silico ADMET Prediction -- Opportunities and Considerations in the Application of Artificial Intelligence to Pharmacokinetic Prediction -- Artificial Intelligence in Drug Safety and Metabolism -- Molecule Ideation Using Matched Molecular Pairs.
標題:	Drugs - Design -
ISBN:	9781071617861

Artificial intelligence in drug design /
Artificial intelligence in drug design /edited by Alexander Heifetz. - New York, NY :Humana Press,2022. - xi, 529 p. :ill. (some col.) ;27 cm. - Methods in molecular biology,23901064-3745 ;. - Springer protocols (Series).

Includes bibliographical references and index.

Applications of Artificial Intelligence in Drug Design: Opportunities and Challenges -- Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints -- Fighting COVID-19 with Artificial Intelligence -- Application of Artificial Intelligence and Machine Learning in Drug Discovery -- Deep Learning and Computational Chemistry -- Has Drug Design Augmented by Artificial Intelligence Become a Reality? -- Network Driven Drug Discovery -- Predicting Residence Time of GPCR Ligands with Machine Learning -- De Novo Molecular Design with Chemical Language Models -- Deep Neural Networks for QSAR -- Deep Learning in Structure-Based Drug Design -- Deep Learning Applied to Ligand-Based De Novo Drug Design -- Ultra-High Throughput Protein-Ligand Docking with Deep Learning -- Artificial Intelligence and Quantum Computing as the Next Pharma Disruptors -- Artificial Intelligence in Compound Design -- Artificial Intelligence, Machine Learning, and Deep Learning in Real Life Drug Design Cases -- Artificial Intelligence-Enabled De Novo Design of Novel Compounds that are Synthesizable -- Machine Learning from Omics Data -- Deep Learning in Therapeutic Antibody Development -- Machine Learning for In Silico ADMET Prediction -- Opportunities and Considerations in the Application of Artificial Intelligence to Pharmacokinetic Prediction -- Artificial Intelligence in Drug Safety and Metabolism -- Molecule Ideation Using Matched Molecular Pairs.

This volume looks at applications of artificial intelligence (AI), machine learning (ML), and deep learning (DL) in drug design. The chapters in this book describe how AI/ML/DL approaches can be applied to accelerate and revolutionize traditional drug design approaches such as: structure- and ligand-based, augmented and multi-objective de novo drug design, SAR and big data analysis, prediction of binding/activity, ADMET, pharmacokinetics and drug-target residence time, precision medicine and selection of favorable chemical synthetic routes. How broadly are these approaches applied and where do they maximally impact productivity today and potentially in the near future. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary software and tools, step-by-step, readily reproducible modeling protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and unique, Artificial Intelligence in Drug Design is a valuable resource for structural and molecular biologists, computational and medicinal chemists, pharmacologists and drug designers.

ISBN: 9781071617861EUR219.99Subjects--Topical Terms:

752557
Drugs
--Design

LC Class. No.: RS420 / .A78 2022

Dewey Class. No.: 615.190028563

Artificial intelligence in drug design /
LDR:03422cam a2200229 a 4500 001 2259317
005 20220222124027.0
008 220502s2022 nyua b 001 0 eng d
020 $a 9781071617861 $q (hbk.) : $c EUR219.99
020 $a 1071617869 $q (hbk.)
020 $z 9781071617878 $q (ebook)
035 $a (OCoLC)1250308585
040 $a YDX $b eng $e aacr2 $c YDX $d UKMGB $d OCLCO $d OCLCF $d HNK $d OCLCO
050 # 4 $a RS420 $b .A78 2022
082 0 4 $a 615.190028563 $2 23
245 0 0 $a Artificial intelligence in drug design / $c edited by Alexander Heifetz.
260 # $a New York, NY : $b Humana Press, $c 2022.
300 $a xi, 529 p. : $b ill. (some col.) ; $c 27 cm.
490 1 $a Methods in molecular biology, $x 1064-3745 ; $v 2390
490 1 $a Springer protocols, $x 1949-2448
504 $a Includes bibliographical references and index.
505 0 # $a Applications of Artificial Intelligence in Drug Design: Opportunities and Challenges -- Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints -- Fighting COVID-19 with Artificial Intelligence -- Application of Artificial Intelligence and Machine Learning in Drug Discovery -- Deep Learning and Computational Chemistry -- Has Drug Design Augmented by Artificial Intelligence Become a Reality? -- Network Driven Drug Discovery -- Predicting Residence Time of GPCR Ligands with Machine Learning -- De Novo Molecular Design with Chemical Language Models -- Deep Neural Networks for QSAR -- Deep Learning in Structure-Based Drug Design -- Deep Learning Applied to Ligand-Based De Novo Drug Design -- Ultra-High Throughput Protein-Ligand Docking with Deep Learning -- Artificial Intelligence and Quantum Computing as the Next Pharma Disruptors -- Artificial Intelligence in Compound Design -- Artificial Intelligence, Machine Learning, and Deep Learning in Real Life Drug Design Cases -- Artificial Intelligence-Enabled De Novo Design of Novel Compounds that are Synthesizable -- Machine Learning from Omics Data -- Deep Learning in Therapeutic Antibody Development -- Machine Learning for In Silico ADMET Prediction -- Opportunities and Considerations in the Application of Artificial Intelligence to Pharmacokinetic Prediction -- Artificial Intelligence in Drug Safety and Metabolism -- Molecule Ideation Using Matched Molecular Pairs.
520 # $a This volume looks at applications of artificial intelligence (AI), machine learning (ML), and deep learning (DL) in drug design. The chapters in this book describe how AI/ML/DL approaches can be applied to accelerate and revolutionize traditional drug design approaches such as: structure- and ligand-based, augmented and multi-objective de novo drug design, SAR and big data analysis, prediction of binding/activity, ADMET, pharmacokinetics and drug-target residence time, precision medicine and selection of favorable chemical synthetic routes. How broadly are these approaches applied and where do they maximally impact productivity today and potentially in the near future. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary software and tools, step-by-step, readily reproducible modeling protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and unique, Artificial Intelligence in Drug Design is a valuable resource for structural and molecular biologists, computational and medicinal chemists, pharmacologists and drug designers.
650 # 0 $a Drugs $x Design $x Data processing. $3 752557
650 # 0 $a Artificial intelligence $x Medical applications. $3 900591
830 0 $a Springer protocols (Series) $x 1949-2448 $3 3199413
830 0 $a Methods in molecular biology (Clifton, N.J.) ; $v v. 2390. $3 3565832